Skip to content
2000
Volume 10, Issue 6
  • ISSN: 1566-5232
  • E-ISSN: 1875-5631

Abstract

The use of recombinant adeno-associated viral vectors (rAAVs) as gene transfer tools has increased dramatically during the past several years, establishing AAV as the vector of choice for many therapeutic applications. With the steady advance of the field toward clinical studies, and the isolation and engineering of several novel AAV serotypes, efficient, scalable, and versatile production and purification methods are continuously under development. Here, we review the current state of the art in the various production and purification methods for rAAVs. Classical parameters and methodologies to characterize rAAV stocks will be also discussed.

Loading

Article metrics loading...

/content/journals/cgt/10.2174/156652310793797685
2010-12-01
2024-12-23
Loading full text...

Full text loading...

/content/journals/cgt/10.2174/156652310793797685
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test